Parallax Volatility Advisers
BSTC

Parallax Volatility Advisers’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Parallax Volatility Advisers’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-882
Closed -$38K – 4915
2017
Q4 		$38K Buy
+882
New +$39.6K ﹤0.01% 3367

Other funds holding BSTC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Parallax Volatility Advisers's BSTC Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of BioSpecifics Technologies Corp. (BSTC) in Q1 2018, closing a stake of 882 shares — an estimated $38K sold.

Parallax Volatility Advisers first reported a position in BSTC in Q4 2017 and held it in 1 quarter. The position peaked at $38K in Q4 2017. 78 funds tracked by Wall St. Rank hold BSTC as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining BioSpecifics Technologies Corp. position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 882 BioSpecifics Technologies Corp. shares in Q1 2018, an estimated $38K.
  • Parallax Volatility Advisers first reported a position in BioSpecifics Technologies Corp. in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's BioSpecifics Technologies Corp. position peaked at $38K in Q4 2017.
  • 78 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.